Do you want to read an article? Please log in or register.
XALOC-1: Clinical remission over 2-years with benralizumab in severe eosinophilic asthma
Asthma
COMMENTED
Related content
RECOMMENDED
Asthma
Long-Term Clinical Remission on Benralizumab Treatment in Severe Eosinophilic Asthma: A Four-Year Real-Life Study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Quarato CMI, Tondo P, Lacedonia D, Soccio P, Pescatore D, Baccellieri ML, Lepore G, Foschino Barbaro MP, Scioscia G
doi: 10.3390/jcm14062075
RECOMMENDED
Asthma
Clinical Remission Outcome in Chinese Patients With Severe Asthma With an Eosinophilic Phenotype Receiving Mepolizumab: A Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Allergy Asthma Immunol Res
Chen R, Dai Y, Yang D, Liu C, Han W, Gu W, Cao J, Zhou Q, Howarth P, Weng S, Xiong C, Huang J, Liang P, Zhong N, 201536 Study Group
doi: 10.4168/aair.2025.17.4.473
Asthma
Early and Sustained Clinical Benefits of Benralizumab in Severe Eosinophilic Asthma: Findings from the ORBE II Study
J Clin Med
Ausín P, Navarrete-Rouco ME, Carazo L, Sanchez-Trincado JL, Luzon E, Nuevo J, Santín M, Sánchez J, Padilla-Galo A
doi: 10.3390/jcm14093011
AsthmaRespiratory Tract Infection
Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register
Respir Med
Hansen S, Håkansson KEJ, Soendergaard MB, Bjerrum AS, Schmid JM, Johansson SL, Rasmussen LM, Johnsen CR, von Bülow A, Bonnesen B, Krogh NS, Hilberg O, Dongo L, Vijdea R, Ulrik CS, Porsbjerg C
doi: 10.1016/j.rmed.2025.108203
RECOMMENDED
Asthma
Early and Sustained Response to Benralizumab in Severe, Eosinophilic Asthma: A Real-World Observational Study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Stolz D, Schuoler C, Charbonnier F, Bridevaux PO, Jandus P, Leuppi JD, Pavlov N, Piecyk A, Rothe T
doi: 10.2147/JAA.S495867
Asthma
Benralizumab In Severe Eosinophilic Asthma: A Real-Life Data From Türkiye
Respir Med
Çelebi Sözener Z, Özdel Öztürk B, Şahinoğlu E, Köylüce S, Türk M, Aydın Ö, Sin BA, Mungan D, Yılmaz İ, Bavbek S
doi: 10.1016/j.rmed.2025.108332
Asthma
Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)
Allergy Asthma Immunol Res
Park SY, Lee D, Kim JH, Lee Y, Ban GY, Sim DW, Kwon JW, Kim SR, Song WJ, Park HW, Chang YS, Koh YI, Lee BJ, Park HS, Cho YS, Kim SH
doi: 10.4168/aair.2025.17.3.384
Asthma
ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up
Respir Med
Pini L, Caminati M, Maule M, Bagnasco D, Beghè B, Bondi B, Braido F, Cameli P, Caruso C, Crimi C, El Masri Y, Giordani J, Guarnieri G, Latorre M, Mastrototaro A, Menzella F, Micheletto C, Pini A, Piras S, Spanevello A, Vianello A, Visca D, Zappa M, Zurlo M, Paggiaro P, Blasi F, Canonica GW, Senna G, Benoni R, SANI study group
doi: 10.1016/j.rmed.2025.108198
Asthma
FEV(1) Decline and Clinical Predictors in Asthma after 10 Years of Follow-Up: BMI as a Modifiable Risk Factor
Respir Med
Díez Sierra J, Medina Gallardo JF, Muñoz Sánchez B, León Lloreda A, Romero Falcón A, Álvarez-Gutiérrez FJ
doi: 10.1016/j.rmed.2025.108247